Satish Garg
Concepts (663)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypoglycemic Agents | 101 | 2025 | 1219 | 17.680 |
Why?
| Diabetes Mellitus, Type 1 | 151 | 2025 | 3628 | 16.950 |
Why?
| Blood Glucose | 115 | 2025 | 2097 | 13.140 |
Why?
| Blood Glucose Self-Monitoring | 70 | 2025 | 601 | 12.590 |
Why?
| Insulin | 85 | 2025 | 2325 | 10.390 |
Why?
| Diabetes Mellitus, Type 2 | 58 | 2025 | 2439 | 9.360 |
Why?
| Diabetes Mellitus | 32 | 2024 | 1000 | 8.060 |
Why?
| Hypoglycemia | 50 | 2023 | 427 | 6.920 |
Why?
| Insulin Infusion Systems | 38 | 2024 | 363 | 5.040 |
Why?
| Monitoring, Ambulatory | 17 | 2017 | 83 | 4.340 |
Why?
| Myometrium | 9 | 2021 | 37 | 4.230 |
Why?
| Buffaloes | 11 | 2021 | 12 | 4.210 |
Why?
| Diabetic Ketoacidosis | 12 | 2024 | 197 | 3.670 |
Why?
| Spermatozoa | 8 | 2024 | 91 | 3.590 |
Why?
| Periodicals as Topic | 7 | 2020 | 204 | 3.230 |
Why?
| Biosimilar Pharmaceuticals | 6 | 2020 | 20 | 3.190 |
Why?
| Hyperglycemia | 17 | 2022 | 328 | 3.120 |
Why?
| Insulin Glargine | 25 | 2022 | 81 | 3.080 |
Why?
| Glycosides | 10 | 2024 | 37 | 2.990 |
Why?
| Uterine Contraction | 8 | 2021 | 17 | 2.850 |
Why?
| Pregnancy in Diabetics | 13 | 2023 | 118 | 2.760 |
Why?
| Sperm Motility | 7 | 2024 | 30 | 2.630 |
Why?
| Dog Diseases | 4 | 2021 | 51 | 2.600 |
Why?
| Insulin Lispro | 14 | 2022 | 39 | 2.490 |
Why?
| Insulin Aspart | 9 | 2020 | 26 | 2.440 |
Why?
| Biomedical Technology | 5 | 2023 | 41 | 2.260 |
Why?
| Mercury | 4 | 2025 | 40 | 2.220 |
Why?
| Insulin, Long-Acting | 21 | 2022 | 62 | 2.190 |
Why?
| Overweight | 4 | 2025 | 531 | 2.150 |
Why?
| Humans | 209 | 2025 | 129248 | 2.130 |
Why?
| Pancreas, Artificial | 5 | 2024 | 70 | 2.120 |
Why?
| Cytokines | 7 | 2021 | 2013 | 2.080 |
Why?
| Calcium | 9 | 2024 | 1212 | 1.970 |
Why?
| Lead | 3 | 2024 | 56 | 1.810 |
Why?
| Sperm Capacitation | 6 | 2021 | 12 | 1.670 |
Why?
| Plant Extracts | 5 | 2019 | 198 | 1.640 |
Why?
| Telemedicine | 6 | 2021 | 789 | 1.630 |
Why?
| Female | 118 | 2025 | 68543 | 1.560 |
Why?
| Antioxidants | 5 | 2020 | 558 | 1.560 |
Why?
| Adult | 87 | 2025 | 35495 | 1.550 |
Why?
| Male | 102 | 2025 | 63501 | 1.490 |
Why?
| Glucagon-Like Peptides | 4 | 2025 | 50 | 1.460 |
Why?
| Sepsis | 3 | 2023 | 572 | 1.420 |
Why?
| Theileriasis | 2 | 2020 | 2 | 1.380 |
Why?
| Animals | 52 | 2025 | 35307 | 1.380 |
Why?
| Insulins | 2 | 2024 | 37 | 1.380 |
Why?
| Cattle | 9 | 2024 | 977 | 1.340 |
Why?
| Mite Infestations | 2 | 2020 | 6 | 1.320 |
Why?
| Injections, Subcutaneous | 11 | 2021 | 147 | 1.320 |
Why?
| rho-Associated Kinases | 3 | 2021 | 87 | 1.240 |
Why?
| Vasoconstriction | 2 | 2022 | 199 | 1.230 |
Why?
| Calcium Signaling | 3 | 2021 | 250 | 1.220 |
Why?
| Middle Aged | 55 | 2025 | 31087 | 1.210 |
Why?
| Postprandial Period | 5 | 2020 | 104 | 1.200 |
Why?
| Obesity | 4 | 2025 | 2879 | 1.180 |
Why?
| Pre-Eclampsia | 10 | 2023 | 187 | 1.170 |
Why?
| Trace Elements | 2 | 2020 | 49 | 1.160 |
Why?
| Diabetes Complications | 5 | 2020 | 224 | 1.120 |
Why?
| Drug Therapy, Combination | 14 | 2021 | 1040 | 1.100 |
Why?
| Trypanosomiasis | 2 | 2017 | 5 | 1.100 |
Why?
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 260 | 1.100 |
Why?
| 3-Hydroxybutyric Acid | 3 | 2024 | 15 | 1.090 |
Why?
| Insulin, Isophane | 6 | 2017 | 21 | 1.070 |
Why?
| Dermatitis, Atopic | 2 | 2021 | 319 | 1.050 |
Why?
| Pandemics | 5 | 2022 | 1482 | 1.050 |
Why?
| Rats, Wistar | 11 | 2020 | 441 | 1.040 |
Why?
| Drugs, Investigational | 2 | 2017 | 32 | 1.020 |
Why?
| Protein Kinase C | 2 | 2018 | 260 | 1.010 |
Why?
| Histamine | 2 | 2017 | 65 | 0.980 |
Why?
| Pneumonia, Viral | 2 | 2020 | 339 | 0.960 |
Why?
| Acrosome Reaction | 2 | 2024 | 3 | 0.960 |
Why?
| Coronavirus Infections | 2 | 2020 | 333 | 0.950 |
Why?
| Acrosome | 1 | 2024 | 5 | 0.920 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2013 | 45 | 0.910 |
Why?
| Uterus | 6 | 2021 | 207 | 0.880 |
Why?
| Biomedical Research | 8 | 2017 | 637 | 0.880 |
Why?
| Monitoring, Physiologic | 6 | 2023 | 265 | 0.870 |
Why?
| Treatment Outcome | 22 | 2025 | 10199 | 0.860 |
Why?
| Reproducibility of Results | 14 | 2025 | 3079 | 0.850 |
Why?
| Diabetic Nephropathies | 2 | 2025 | 284 | 0.840 |
Why?
| Weight Loss | 4 | 2025 | 732 | 0.840 |
Why?
| Angiotensin II | 1 | 2023 | 95 | 0.800 |
Why?
| Spleen | 3 | 2020 | 506 | 0.800 |
Why?
| Cross-Over Studies | 10 | 2020 | 521 | 0.790 |
Why?
| Dinoprost | 2 | 2021 | 44 | 0.780 |
Why?
| Receptor, Notch3 | 1 | 2022 | 5 | 0.780 |
Why?
| Glucagon-Like Peptide 1 | 3 | 2013 | 112 | 0.780 |
Why?
| Sulfones | 2 | 2020 | 108 | 0.770 |
Why?
| Benzamides | 2 | 2020 | 207 | 0.760 |
Why?
| Aorta | 2 | 2022 | 408 | 0.760 |
Why?
| Pregnancy | 23 | 2023 | 6391 | 0.740 |
Why?
| Nifedipine | 6 | 2021 | 29 | 0.730 |
Why?
| Intermediate Filament Proteins | 1 | 2021 | 57 | 0.730 |
Why?
| Administration, Inhalation | 4 | 2018 | 666 | 0.730 |
Why?
| Glucose | 6 | 2024 | 1001 | 0.730 |
Why?
| Signal Transduction | 6 | 2024 | 4926 | 0.730 |
Why?
| Arterial Pressure | 1 | 2022 | 118 | 0.720 |
Why?
| Dose-Response Relationship, Drug | 14 | 2020 | 2008 | 0.720 |
Why?
| TRPC Cation Channels | 2 | 2021 | 14 | 0.720 |
Why?
| Type C Phospholipases | 2 | 2018 | 72 | 0.720 |
Why?
| Dogs | 5 | 2021 | 382 | 0.710 |
Why?
| Insulin Antibodies | 2 | 2020 | 105 | 0.710 |
Why?
| Trypanosoma | 2 | 2017 | 7 | 0.710 |
Why?
| Young Adult | 25 | 2025 | 12388 | 0.710 |
Why?
| Mitochondrial Membranes | 1 | 2021 | 38 | 0.700 |
Why?
| Biopolymers | 1 | 2020 | 32 | 0.700 |
Why?
| Endometritis | 2 | 2017 | 4 | 0.700 |
Why?
| Gelatin | 1 | 2020 | 42 | 0.700 |
Why?
| Calcium Channel Blockers | 6 | 2021 | 161 | 0.700 |
Why?
| Theileria annulata | 1 | 2020 | 1 | 0.690 |
Why?
| Chitosan | 1 | 2020 | 32 | 0.690 |
Why?
| Protein Precursors | 1 | 2021 | 128 | 0.690 |
Why?
| Betacoronavirus | 2 | 2020 | 248 | 0.690 |
Why?
| Copper Sulfate | 1 | 2020 | 8 | 0.690 |
Why?
| Exophthalmos | 1 | 2020 | 17 | 0.680 |
Why?
| Diabetic Angiopathies | 6 | 2013 | 261 | 0.680 |
Why?
| Mutagens | 1 | 2020 | 17 | 0.680 |
Why?
| Cattle Diseases | 1 | 2020 | 20 | 0.680 |
Why?
| Sodium-Glucose Transporter 1 | 2 | 2017 | 10 | 0.680 |
Why?
| Selenium | 1 | 2020 | 36 | 0.680 |
Why?
| Sulfonylurea Compounds | 2 | 2018 | 46 | 0.670 |
Why?
| Calcium Channels | 2 | 2018 | 164 | 0.670 |
Why?
| Patient Education as Topic | 6 | 2020 | 737 | 0.670 |
Why?
| Peste-des-petits-ruminants virus | 1 | 2019 | 1 | 0.660 |
Why?
| Polyalthia | 1 | 2019 | 1 | 0.660 |
Why?
| Oleic Acid | 1 | 2020 | 39 | 0.660 |
Why?
| Newcastle disease virus | 1 | 2019 | 17 | 0.660 |
Why?
| Infusions, Subcutaneous | 4 | 2016 | 21 | 0.660 |
Why?
| Mites | 1 | 2019 | 6 | 0.650 |
Why?
| Aged | 25 | 2024 | 22032 | 0.650 |
Why?
| Isoproterenol | 1 | 2020 | 115 | 0.650 |
Why?
| Peroxidase | 2 | 2017 | 174 | 0.640 |
Why?
| Down-Regulation | 1 | 2022 | 636 | 0.640 |
Why?
| Toll-Like Receptors | 1 | 2020 | 179 | 0.620 |
Why?
| Potassium Channels | 1 | 2020 | 149 | 0.620 |
Why?
| Oxidative Stress | 4 | 2020 | 1265 | 0.620 |
Why?
| Cardiovascular Diseases | 3 | 2025 | 2003 | 0.610 |
Why?
| Endocannabinoids | 2 | 2019 | 53 | 0.610 |
Why?
| Uterine Artery | 1 | 2019 | 78 | 0.610 |
Why?
| Mercuric Chloride | 1 | 2018 | 2 | 0.600 |
Why?
| Biosensing Techniques | 2 | 2018 | 118 | 0.600 |
Why?
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2018 | 19 | 0.590 |
Why?
| Wound Healing | 1 | 2020 | 305 | 0.580 |
Why?
| Adolescent | 30 | 2022 | 20303 | 0.580 |
Why?
| Voltage-Gated Sodium Channels | 1 | 2017 | 5 | 0.580 |
Why?
| Weight Gain | 6 | 2024 | 509 | 0.580 |
Why?
| Tocolysis | 1 | 2017 | 4 | 0.580 |
Why?
| Vasodilation | 2 | 2019 | 476 | 0.580 |
Why?
| Ethanolamines | 1 | 2017 | 17 | 0.580 |
Why?
| Eucalyptus | 1 | 2017 | 7 | 0.570 |
Why?
| Double-Blind Method | 9 | 2024 | 1875 | 0.570 |
Why?
| KATP Channels | 1 | 2017 | 20 | 0.570 |
Why?
| Potassium Channels, Voltage-Gated | 1 | 2018 | 50 | 0.570 |
Why?
| Oxytocin | 2 | 2016 | 48 | 0.570 |
Why?
| Immunoglobulin E | 1 | 2019 | 329 | 0.560 |
Why?
| Endothelium, Vascular | 3 | 2019 | 901 | 0.560 |
Why?
| Interleukins | 1 | 2019 | 241 | 0.560 |
Why?
| Norepinephrine | 1 | 2018 | 210 | 0.560 |
Why?
| Hydrogen Sulfide | 1 | 2017 | 42 | 0.560 |
Why?
| Self Care | 4 | 2013 | 365 | 0.550 |
Why?
| Hospitalization | 2 | 2024 | 2052 | 0.550 |
Why?
| Syringes | 3 | 2013 | 43 | 0.540 |
Why?
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.540 |
Why?
| Mitochondria | 2 | 2021 | 877 | 0.540 |
Why?
| Coinfection | 1 | 2018 | 131 | 0.540 |
Why?
| Reactive Oxygen Species | 1 | 2020 | 595 | 0.540 |
Why?
| Cadmium | 1 | 2017 | 67 | 0.540 |
Why?
| Therapies, Investigational | 1 | 2017 | 17 | 0.540 |
Why?
| Inflammation Mediators | 1 | 2020 | 505 | 0.530 |
Why?
| Muscle Relaxation | 1 | 2016 | 20 | 0.520 |
Why?
| Minerals | 1 | 2016 | 39 | 0.520 |
Why?
| Cholinesterases | 1 | 2016 | 10 | 0.520 |
Why?
| Diffusion of Innovation | 1 | 2017 | 97 | 0.510 |
Why?
| Calcium Channels, L-Type | 1 | 2017 | 117 | 0.500 |
Why?
| Ambulatory Care Facilities | 2 | 2023 | 226 | 0.500 |
Why?
| Body Mass Index | 8 | 2025 | 2272 | 0.500 |
Why?
| Receptors, Adrenergic, beta | 1 | 2016 | 127 | 0.490 |
Why?
| Insulin, Regular, Human | 3 | 2024 | 43 | 0.490 |
Why?
| Myocytes, Cardiac | 1 | 2020 | 499 | 0.490 |
Why?
| United States | 17 | 2025 | 13828 | 0.490 |
Why?
| Registries | 6 | 2024 | 1895 | 0.480 |
Why?
| Disposable Equipment | 2 | 2013 | 19 | 0.480 |
Why?
| Vitamins | 1 | 2016 | 173 | 0.480 |
Why?
| Consensus | 7 | 2023 | 615 | 0.480 |
Why?
| Insulin Detemir | 5 | 2017 | 8 | 0.470 |
Why?
| Drug Delivery Systems | 2 | 2018 | 333 | 0.470 |
Why?
| Prospective Studies | 14 | 2025 | 7121 | 0.460 |
Why?
| Gene Expression | 1 | 2020 | 1466 | 0.460 |
Why?
| Glucagon-Like Peptide-2 Receptor | 2 | 2025 | 14 | 0.460 |
Why?
| Gastric Inhibitory Polypeptide | 2 | 2025 | 23 | 0.460 |
Why?
| Biomarkers | 12 | 2025 | 3966 | 0.460 |
Why?
| Rats | 7 | 2020 | 5482 | 0.450 |
Why?
| Drug Administration Schedule | 8 | 2017 | 768 | 0.440 |
Why?
| Withania | 1 | 2013 | 5 | 0.440 |
Why?
| Glucagon | 2 | 2022 | 105 | 0.440 |
Why?
| Antiviral Agents | 1 | 2019 | 712 | 0.430 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2013 | 43 | 0.430 |
Why?
| Retrospective Studies | 10 | 2025 | 14455 | 0.420 |
Why?
| Extracellular Fluid | 1 | 2013 | 31 | 0.420 |
Why?
| Glucosides | 3 | 2019 | 38 | 0.420 |
Why?
| Nervous System Diseases | 1 | 2016 | 252 | 0.420 |
Why?
| Chlorpyrifos | 1 | 2013 | 7 | 0.410 |
Why?
| Benzhydryl Compounds | 3 | 2019 | 66 | 0.410 |
Why?
| History, 21st Century | 3 | 2020 | 183 | 0.410 |
Why?
| Membrane Potential, Mitochondrial | 3 | 2024 | 67 | 0.410 |
Why?
| Microsomes, Liver | 1 | 2013 | 87 | 0.400 |
Why?
| Portal Vein | 1 | 2013 | 108 | 0.400 |
Why?
| Time Factors | 12 | 2021 | 6543 | 0.400 |
Why?
| Myocardial Infarction | 1 | 2020 | 1021 | 0.390 |
Why?
| Ascorbic Acid | 1 | 2013 | 120 | 0.390 |
Why?
| Arsenic | 1 | 2013 | 63 | 0.390 |
Why?
| Pregnancy Outcome | 3 | 2023 | 389 | 0.380 |
Why?
| Pyrazines | 1 | 2013 | 86 | 0.380 |
Why?
| Tocolytic Agents | 2 | 2017 | 15 | 0.370 |
Why?
| Prevalence | 8 | 2020 | 2554 | 0.370 |
Why?
| Patient Preference | 1 | 2013 | 184 | 0.370 |
Why?
| Triazoles | 1 | 2013 | 148 | 0.370 |
Why?
| Needles | 1 | 2011 | 57 | 0.360 |
Why?
| Goats | 2 | 2021 | 26 | 0.360 |
Why?
| Clinical Trials as Topic | 7 | 2022 | 1004 | 0.350 |
Why?
| Adrenergic beta-Agonists | 2 | 2017 | 132 | 0.350 |
Why?
| History, 20th Century | 3 | 2019 | 291 | 0.340 |
Why?
| Blood Chemical Analysis | 2 | 2017 | 96 | 0.340 |
Why?
| DNA Damage | 2 | 2024 | 383 | 0.330 |
Why?
| Water Pollutants, Chemical | 1 | 2013 | 196 | 0.330 |
Why?
| Acetylcholine | 3 | 2019 | 186 | 0.330 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2022 | 171 | 0.320 |
Why?
| Calibration | 3 | 2018 | 140 | 0.320 |
Why?
| Health Care Costs | 4 | 2016 | 367 | 0.320 |
Why?
| China | 4 | 2020 | 192 | 0.320 |
Why?
| Organometallic Compounds | 2 | 2024 | 106 | 0.320 |
Why?
| Pregnancy Trimester, First | 3 | 2020 | 137 | 0.320 |
Why?
| Intention to Treat Analysis | 3 | 2017 | 68 | 0.310 |
Why?
| 4-Aminopyridine | 2 | 2020 | 24 | 0.310 |
Why?
| Research Design | 6 | 2015 | 1043 | 0.310 |
Why?
| Reference Values | 6 | 2023 | 793 | 0.310 |
Why?
| Plant Leaves | 3 | 2019 | 139 | 0.300 |
Why?
| alpha-Tocopherol | 2 | 2020 | 33 | 0.300 |
Why?
| Prediabetic State | 1 | 2011 | 244 | 0.300 |
Why?
| Computer Systems | 2 | 2018 | 44 | 0.290 |
Why?
| Animals, Newborn | 2 | 2020 | 834 | 0.290 |
Why?
| Software | 3 | 2013 | 606 | 0.280 |
Why?
| Blood Pressure | 4 | 2025 | 1736 | 0.280 |
Why?
| Veratridine | 2 | 2017 | 6 | 0.280 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 1702 | 0.280 |
Why?
| Sodium-Glucose Transport Proteins | 2 | 2017 | 2 | 0.270 |
Why?
| Equipment Design | 4 | 2010 | 513 | 0.270 |
Why?
| Child | 11 | 2022 | 20773 | 0.270 |
Why?
| Risk Factors | 8 | 2024 | 9745 | 0.260 |
Why?
| United States Food and Drug Administration | 3 | 2018 | 204 | 0.260 |
Why?
| Nitric Oxide | 3 | 2022 | 895 | 0.260 |
Why?
| Vasodilator Agents | 2 | 2019 | 326 | 0.260 |
Why?
| Journal Impact Factor | 2 | 2020 | 29 | 0.250 |
Why?
| Ruthenium Red | 2 | 2016 | 8 | 0.250 |
Why?
| Diabetic Retinopathy | 2 | 2005 | 177 | 0.250 |
Why?
| Blotting, Western | 3 | 2017 | 1204 | 0.250 |
Why?
| Hypertension | 4 | 2011 | 1242 | 0.250 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2021 | 1202 | 0.250 |
Why?
| Albuminuria | 3 | 2017 | 183 | 0.240 |
Why?
| Tissue Culture Techniques | 2 | 2017 | 74 | 0.240 |
Why?
| Lipoproteins | 2 | 2019 | 171 | 0.240 |
Why?
| Copper | 2 | 2016 | 107 | 0.240 |
Why?
| Exercise | 2 | 2014 | 1925 | 0.240 |
Why?
| Algorithms | 5 | 2018 | 1613 | 0.240 |
Why?
| Phenylephrine | 2 | 2016 | 75 | 0.240 |
Why?
| Large-Conductance Calcium-Activated Potassium Channels | 2 | 2017 | 11 | 0.240 |
Why?
| Fasting | 1 | 2006 | 267 | 0.240 |
Why?
| Glomerular Filtration Rate | 3 | 2025 | 711 | 0.230 |
Why?
| Body Weight | 7 | 2020 | 939 | 0.230 |
Why?
| Semen Analysis | 1 | 2024 | 13 | 0.230 |
Why?
| Calcinosis | 4 | 2010 | 231 | 0.230 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2004 | 35 | 0.230 |
Why?
| Phosphorylation | 2 | 2020 | 1710 | 0.220 |
Why?
| Pyrazoles | 2 | 2018 | 404 | 0.220 |
Why?
| Mass Screening | 1 | 2011 | 1149 | 0.220 |
Why?
| Uridine Diphosphate | 1 | 2023 | 3 | 0.210 |
Why?
| Drug Approval | 1 | 2024 | 87 | 0.210 |
Why?
| Cyclic AMP | 1 | 2024 | 237 | 0.210 |
Why?
| Equipment Failure | 2 | 2018 | 105 | 0.210 |
Why?
| Reproduction | 1 | 2025 | 197 | 0.210 |
Why?
| Dietary Supplements | 2 | 2018 | 534 | 0.210 |
Why?
| Aged, 80 and over | 3 | 2022 | 7055 | 0.200 |
Why?
| Endocrinology | 2 | 2016 | 74 | 0.200 |
Why?
| Receptors, Glucagon | 1 | 2022 | 27 | 0.200 |
Why?
| Vitamin D-Binding Protein | 2 | 2020 | 15 | 0.200 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2021 | 1364 | 0.190 |
Why?
| Safety | 3 | 2009 | 330 | 0.190 |
Why?
| Mice | 5 | 2023 | 16915 | 0.190 |
Why?
| Ketosis | 1 | 2021 | 12 | 0.180 |
Why?
| Mobile Applications | 2 | 2021 | 160 | 0.180 |
Why?
| Reference Standards | 4 | 2017 | 176 | 0.180 |
Why?
| Testis | 2 | 2025 | 144 | 0.180 |
Why?
| Illinois | 1 | 2021 | 39 | 0.180 |
Why?
| Immunization, Passive | 1 | 2021 | 86 | 0.180 |
Why?
| Patient Isolation | 1 | 2021 | 16 | 0.180 |
Why?
| Los Angeles | 1 | 2021 | 63 | 0.180 |
Why?
| Child, Preschool | 5 | 2022 | 10456 | 0.180 |
Why?
| New York City | 1 | 2021 | 80 | 0.180 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2020 | 55 | 0.180 |
Why?
| Environmental Exposure | 1 | 2025 | 462 | 0.170 |
Why?
| Patient Satisfaction | 3 | 2015 | 632 | 0.170 |
Why?
| Micronucleus Tests | 1 | 2020 | 5 | 0.170 |
Why?
| Comet Assay | 1 | 2020 | 17 | 0.170 |
Why?
| Antigens, Viral | 1 | 2021 | 178 | 0.170 |
Why?
| Skin Diseases, Parasitic | 1 | 2020 | 2 | 0.170 |
Why?
| Progesterone | 2 | 2019 | 245 | 0.170 |
Why?
| Interleukin-13 | 1 | 2021 | 147 | 0.170 |
Why?
| Incidence | 3 | 2017 | 2636 | 0.170 |
Why?
| Chromium | 1 | 2020 | 13 | 0.170 |
Why?
| Uncoupling Protein 2 | 1 | 2020 | 8 | 0.170 |
Why?
| Practice Guidelines as Topic | 3 | 2019 | 1497 | 0.170 |
Why?
| Disease Models, Animal | 2 | 2020 | 4057 | 0.170 |
Why?
| Cardiotoxicity | 1 | 2020 | 33 | 0.170 |
Why?
| Transforming Growth Factor beta1 | 1 | 2020 | 157 | 0.170 |
Why?
| Income | 1 | 2021 | 188 | 0.160 |
Why?
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 1 | 0.160 |
Why?
| Curcumin | 1 | 2020 | 29 | 0.160 |
Why?
| Glycemic Index | 2 | 2009 | 25 | 0.160 |
Why?
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2019 | 10 | 0.160 |
Why?
| Cyclooxygenase 1 | 1 | 2019 | 26 | 0.160 |
Why?
| Vero Cells | 1 | 2019 | 65 | 0.160 |
Why?
| Virus Internalization | 1 | 2019 | 47 | 0.160 |
Why?
| Lipid Peroxidation | 1 | 2020 | 151 | 0.160 |
Why?
| Haptoglobins | 1 | 2019 | 52 | 0.160 |
Why?
| Diabetes, Gestational | 1 | 2023 | 308 | 0.160 |
Why?
| Canagliflozin | 1 | 2019 | 9 | 0.160 |
Why?
| Host-Parasite Interactions | 1 | 2020 | 103 | 0.160 |
Why?
| Area Under Curve | 3 | 2015 | 304 | 0.160 |
Why?
| Tyrosine | 1 | 2020 | 223 | 0.160 |
Why?
| Adamantane | 1 | 2019 | 16 | 0.160 |
Why?
| Immunity, Cellular | 2 | 2018 | 265 | 0.160 |
Why?
| Liver Cirrhosis | 1 | 2021 | 279 | 0.150 |
Why?
| Dipeptides | 1 | 2019 | 47 | 0.150 |
Why?
| TRPV Cation Channels | 1 | 2019 | 36 | 0.150 |
Why?
| California | 1 | 2020 | 400 | 0.150 |
Why?
| Ion Channels | 1 | 2019 | 133 | 0.150 |
Why?
| Congresses as Topic | 2 | 2020 | 216 | 0.150 |
Why?
| Vitamin D | 2 | 2020 | 385 | 0.150 |
Why?
| Meals | 1 | 2020 | 119 | 0.150 |
Why?
| Methyldopa | 1 | 2018 | 7 | 0.150 |
Why?
| Patient Care Planning | 1 | 2019 | 146 | 0.150 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2018 | 40 | 0.150 |
Why?
| Sensitivity and Specificity | 4 | 2009 | 1837 | 0.150 |
Why?
| Self Efficacy | 1 | 2002 | 373 | 0.150 |
Why?
| Organ Culture Techniques | 1 | 2018 | 153 | 0.150 |
Why?
| Aminooxyacetic Acid | 1 | 2017 | 1 | 0.150 |
Why?
| Sodium Channel Agonists | 1 | 2017 | 1 | 0.150 |
Why?
| Receptors, Adrenergic, beta-3 | 1 | 2017 | 4 | 0.150 |
Why?
| Sodium Bicarbonate | 1 | 2018 | 37 | 0.140 |
Why?
| International Agencies | 1 | 2017 | 29 | 0.140 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 530 | 0.140 |
Why?
| Injections | 1 | 2018 | 174 | 0.140 |
Why?
| Administration, Oral | 2 | 2017 | 785 | 0.140 |
Why?
| Hemoglobin A | 1 | 2017 | 22 | 0.140 |
Why?
| Serum Amyloid A Protein | 1 | 2017 | 31 | 0.140 |
Why?
| Malondialdehyde | 1 | 2017 | 28 | 0.140 |
Why?
| Equivalence Trials as Topic | 1 | 2017 | 7 | 0.140 |
Why?
| Analysis of Variance | 1 | 2020 | 1288 | 0.140 |
Why?
| Glyburide | 1 | 2017 | 35 | 0.140 |
Why?
| Methanol | 1 | 2017 | 35 | 0.140 |
Why?
| Toll-Like Receptor 9 | 1 | 2017 | 31 | 0.140 |
Why?
| Alkynes | 1 | 2017 | 54 | 0.140 |
Why?
| Biomechanical Phenomena | 1 | 2021 | 757 | 0.140 |
Why?
| Least-Squares Analysis | 1 | 2017 | 78 | 0.140 |
Why?
| Data Interpretation, Statistical | 1 | 2019 | 336 | 0.140 |
Why?
| Protein Carbonylation | 1 | 2017 | 56 | 0.140 |
Why?
| HLA-DQ Antigens | 1 | 2018 | 179 | 0.140 |
Why?
| Adipokines | 1 | 2017 | 47 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 758 | 0.140 |
Why?
| Solvents | 1 | 2017 | 108 | 0.140 |
Why?
| Patient Compliance | 2 | 2013 | 563 | 0.140 |
Why?
| Patient Dropouts | 1 | 2017 | 64 | 0.140 |
Why?
| Phytotherapy | 1 | 2017 | 79 | 0.140 |
Why?
| Propanolamines | 1 | 2017 | 97 | 0.140 |
Why?
| Longitudinal Studies | 6 | 2020 | 2716 | 0.140 |
Why?
| Islet Amyloid Polypeptide | 3 | 2013 | 46 | 0.140 |
Why?
| Immunization | 1 | 2019 | 411 | 0.140 |
Why?
| Antibodies, Viral | 1 | 2021 | 601 | 0.140 |
Why?
| Clinical Protocols | 1 | 2018 | 254 | 0.140 |
Why?
| Cyclooxygenase 2 | 1 | 2017 | 177 | 0.130 |
Why?
| Anniversaries and Special Events | 1 | 2017 | 16 | 0.130 |
Why?
| Antigen Presentation | 1 | 2018 | 207 | 0.130 |
Why?
| Fatty Acids, Nonesterified | 1 | 2017 | 160 | 0.130 |
Why?
| Computer-Aided Design | 1 | 2017 | 42 | 0.130 |
Why?
| Furans | 1 | 2016 | 23 | 0.130 |
Why?
| Glycine | 1 | 2017 | 165 | 0.130 |
Why?
| Uric Acid | 1 | 2018 | 161 | 0.130 |
Why?
| Cell Survival | 1 | 2020 | 1074 | 0.130 |
Why?
| Up-Regulation | 1 | 2020 | 839 | 0.130 |
Why?
| Indicators and Reagents | 1 | 2016 | 109 | 0.130 |
Why?
| Coronary Artery Disease | 3 | 2010 | 679 | 0.130 |
Why?
| Combined Modality Therapy | 2 | 2017 | 1199 | 0.130 |
Why?
| Oleaceae | 1 | 2016 | 1 | 0.130 |
Why?
| Sympathomimetics | 1 | 2016 | 23 | 0.130 |
Why?
| Antihypertensive Agents | 3 | 2012 | 485 | 0.130 |
Why?
| Piperidines | 1 | 2018 | 198 | 0.130 |
Why?
| In Vitro Techniques | 2 | 2016 | 1085 | 0.130 |
Why?
| Antibody Formation | 1 | 2018 | 291 | 0.130 |
Why?
| Socioeconomic Factors | 1 | 2021 | 1209 | 0.130 |
Why?
| Lung | 1 | 2009 | 3926 | 0.130 |
Why?
| Cysteine | 1 | 2017 | 195 | 0.130 |
Why?
| Pilot Projects | 2 | 2018 | 1584 | 0.130 |
Why?
| Drug Hypersensitivity | 1 | 2017 | 81 | 0.130 |
Why?
| Leptin | 2 | 2017 | 219 | 0.130 |
Why?
| Comorbidity | 1 | 2021 | 1544 | 0.130 |
Why?
| Eating | 3 | 2009 | 368 | 0.130 |
Why?
| Anti-Inflammatory Agents | 1 | 2020 | 480 | 0.130 |
Why?
| Amyloid | 2 | 2007 | 85 | 0.130 |
Why?
| Aniline Compounds | 1 | 2016 | 97 | 0.130 |
Why?
| Estradiol | 1 | 2019 | 494 | 0.130 |
Why?
| Drug Design | 1 | 2017 | 156 | 0.130 |
Why?
| Forecasting | 2 | 2016 | 359 | 0.130 |
Why?
| Membrane Potentials | 1 | 2016 | 293 | 0.130 |
Why?
| Moringa oleifera | 1 | 2015 | 3 | 0.120 |
Why?
| Incretins | 1 | 2015 | 18 | 0.120 |
Why?
| Vascular Stiffness | 1 | 2021 | 467 | 0.120 |
Why?
| Interleukin-10 | 1 | 2017 | 300 | 0.120 |
Why?
| Imidazoles | 1 | 2016 | 234 | 0.120 |
Why?
| RNA, Messenger | 1 | 2023 | 2703 | 0.120 |
Why?
| Toll-Like Receptor 4 | 1 | 2017 | 263 | 0.120 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 286 | 0.120 |
Why?
| Postnatal Care | 1 | 2016 | 71 | 0.120 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 2 | 2013 | 252 | 0.120 |
Why?
| Cells, Cultured | 2 | 2020 | 4076 | 0.120 |
Why?
| Early Diagnosis | 2 | 2015 | 233 | 0.120 |
Why?
| Disease Management | 1 | 2019 | 588 | 0.120 |
Why?
| Self-Management | 1 | 2017 | 163 | 0.110 |
Why?
| Materials Testing | 2 | 2017 | 343 | 0.110 |
Why?
| Vitamin D Deficiency | 2 | 2020 | 176 | 0.110 |
Why?
| Cholesterol, HDL | 1 | 2015 | 205 | 0.110 |
Why?
| Estrenes | 1 | 2014 | 16 | 0.110 |
Why?
| Case-Control Studies | 2 | 2019 | 3377 | 0.110 |
Why?
| Pyrrolidinones | 1 | 2014 | 29 | 0.110 |
Why?
| Inflammation | 1 | 2005 | 2737 | 0.110 |
Why?
| Gastrins | 1 | 2013 | 9 | 0.110 |
Why?
| Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.110 |
Why?
| Colorado | 2 | 2020 | 4406 | 0.110 |
Why?
| Allylamine | 1 | 2013 | 8 | 0.110 |
Why?
| Bromocriptine | 1 | 2013 | 29 | 0.110 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2013 | 22 | 0.110 |
Why?
| Kidney Diseases | 1 | 2017 | 382 | 0.110 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2014 | 89 | 0.110 |
Why?
| Staining and Labeling | 1 | 2014 | 141 | 0.110 |
Why?
| Prenatal Care | 1 | 2016 | 274 | 0.110 |
Why?
| Escherichia coli | 1 | 2017 | 766 | 0.110 |
Why?
| Catecholamines | 1 | 2013 | 96 | 0.110 |
Why?
| Staphylococcus aureus | 1 | 2017 | 434 | 0.110 |
Why?
| Immunohistochemistry | 1 | 2017 | 1691 | 0.100 |
Why?
| Immunologic Factors | 1 | 2015 | 230 | 0.100 |
Why?
| Age Factors | 2 | 2019 | 3140 | 0.100 |
Why?
| Enzyme Inhibitors | 1 | 2016 | 827 | 0.100 |
Why?
| Chemistry, Pharmaceutical | 1 | 2013 | 107 | 0.100 |
Why?
| Toxicity Tests, Subacute | 1 | 2013 | 1 | 0.100 |
Why?
| Quality of Life | 5 | 2016 | 2685 | 0.100 |
Why?
| Coronary Disease | 2 | 2007 | 385 | 0.100 |
Why?
| Menopause | 1 | 2016 | 297 | 0.100 |
Why?
| Cooperative Behavior | 1 | 2016 | 433 | 0.100 |
Why?
| Sitagliptin Phosphate | 1 | 2013 | 31 | 0.100 |
Why?
| Autoantibodies | 2 | 2018 | 1467 | 0.100 |
Why?
| Leadership | 1 | 2017 | 353 | 0.100 |
Why?
| Oxidation-Reduction | 1 | 2016 | 1028 | 0.100 |
Why?
| Patient Selection | 2 | 2009 | 662 | 0.100 |
Why?
| Circadian Rhythm | 4 | 2015 | 413 | 0.100 |
Why?
| Thiazolidinediones | 1 | 2013 | 137 | 0.100 |
Why?
| Insecticides | 1 | 2013 | 33 | 0.100 |
Why?
| Delayed-Action Preparations | 1 | 2013 | 172 | 0.100 |
Why?
| Islets of Langerhans Transplantation | 1 | 2013 | 63 | 0.100 |
Why?
| T-Lymphocytes | 2 | 2018 | 1933 | 0.100 |
Why?
| Gene Expression Regulation | 2 | 2019 | 2537 | 0.100 |
Why?
| Zinc | 1 | 2015 | 285 | 0.100 |
Why?
| Cell Proliferation | 2 | 2016 | 2374 | 0.090 |
Why?
| Drinking Water | 1 | 2013 | 76 | 0.090 |
Why?
| Internet | 1 | 2016 | 615 | 0.090 |
Why?
| Self Administration | 1 | 2011 | 120 | 0.090 |
Why?
| Carotenoids | 1 | 2011 | 41 | 0.090 |
Why?
| Swine | 1 | 2013 | 760 | 0.090 |
Why?
| Managed Care Programs | 1 | 2011 | 133 | 0.090 |
Why?
| Cohort Studies | 4 | 2019 | 5408 | 0.090 |
Why?
| Home Care Services | 1 | 2013 | 225 | 0.090 |
Why?
| Regression Analysis | 2 | 2010 | 991 | 0.080 |
Why?
| Eicosapentaenoic Acid | 1 | 2010 | 36 | 0.080 |
Why?
| Surveys and Questionnaires | 4 | 2014 | 5382 | 0.080 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 338 | 0.080 |
Why?
| Metformin | 1 | 2013 | 315 | 0.080 |
Why?
| Drug Combinations | 1 | 2010 | 330 | 0.080 |
Why?
| Decision Making | 2 | 2013 | 849 | 0.080 |
Why?
| Carcinogens | 1 | 2009 | 110 | 0.080 |
Why?
| Physicians | 2 | 2017 | 859 | 0.080 |
Why?
| Vital Capacity | 1 | 2009 | 289 | 0.080 |
Why?
| Disease Progression | 3 | 2012 | 2630 | 0.070 |
Why?
| Cross-Sectional Studies | 4 | 2015 | 5045 | 0.070 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 2396 | 0.070 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2018 | 42 | 0.070 |
Why?
| Forced Expiratory Volume | 1 | 2009 | 506 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2013 | 854 | 0.070 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| Norway | 2 | 2019 | 42 | 0.070 |
Why?
| C-Reactive Protein | 2 | 2013 | 400 | 0.070 |
Why?
| Drug Costs | 1 | 2008 | 100 | 0.070 |
Why?
| Sheep | 1 | 2010 | 838 | 0.070 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2007 | 72 | 0.070 |
Why?
| Infusion Pumps, Implantable | 2 | 2004 | 22 | 0.070 |
Why?
| Nebulizers and Vaporizers | 1 | 2007 | 83 | 0.070 |
Why?
| Medication Adherence | 1 | 2011 | 556 | 0.070 |
Why?
| Australia | 2 | 2019 | 243 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 82 | 0.070 |
Why?
| Societies, Medical | 1 | 2010 | 744 | 0.070 |
Why?
| Risk Management | 2 | 2019 | 85 | 0.070 |
Why?
| Infant | 1 | 2020 | 8975 | 0.060 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 198 | 0.060 |
Why?
| Creatinine | 2 | 2018 | 491 | 0.060 |
Why?
| Patient Acceptance of Health Care | 1 | 2012 | 757 | 0.060 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 1094 | 0.060 |
Why?
| Alprostadil | 1 | 2005 | 32 | 0.060 |
Why?
| Immunity, Humoral | 2 | 2016 | 118 | 0.060 |
Why?
| Spermatogenesis | 1 | 2025 | 62 | 0.060 |
Why?
| Barium Compounds | 1 | 2004 | 8 | 0.060 |
Why?
| Organ Size | 2 | 2016 | 446 | 0.060 |
Why?
| Terbutaline | 1 | 2004 | 8 | 0.060 |
Why?
| Potassium Chloride | 1 | 2004 | 39 | 0.060 |
Why?
| Abortifacient Agents, Nonsteroidal | 1 | 2004 | 21 | 0.060 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2004 | 46 | 0.060 |
Why?
| Dinoprostone | 1 | 2005 | 187 | 0.060 |
Why?
| Hyperlipidemias | 1 | 2005 | 126 | 0.060 |
Why?
| Automation | 1 | 2004 | 81 | 0.060 |
Why?
| Albuterol | 1 | 2004 | 102 | 0.060 |
Why?
| Pulmonary Artery | 1 | 2010 | 1095 | 0.050 |
Why?
| Capillaries | 1 | 2004 | 103 | 0.050 |
Why?
| Homeostasis | 1 | 2007 | 605 | 0.050 |
Why?
| Chlorides | 1 | 2004 | 139 | 0.050 |
Why?
| Modems | 1 | 2003 | 1 | 0.050 |
Why?
| Fetal Macrosomia | 1 | 2003 | 62 | 0.050 |
Why?
| Glycation End Products, Advanced | 1 | 2023 | 76 | 0.050 |
Why?
| Transaminases | 1 | 2022 | 23 | 0.050 |
Why?
| Food | 1 | 2004 | 156 | 0.050 |
Why?
| Primary Health Care | 1 | 2013 | 1678 | 0.050 |
Why?
| Congenital Abnormalities | 1 | 2003 | 74 | 0.050 |
Why?
| Pregnant Women | 1 | 2023 | 114 | 0.050 |
Why?
| Costs and Cost Analysis | 1 | 2003 | 201 | 0.050 |
Why?
| Lipoproteins, LDL | 1 | 2022 | 127 | 0.050 |
Why?
| Educational Status | 1 | 2004 | 469 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2020 | 4886 | 0.050 |
Why?
| Ketone Bodies | 1 | 2021 | 15 | 0.050 |
Why?
| Prognosis | 2 | 2020 | 3772 | 0.050 |
Why?
| Preconception Care | 1 | 2002 | 41 | 0.050 |
Why?
| Labor, Obstetric | 1 | 2002 | 58 | 0.050 |
Why?
| Age of Onset | 1 | 2003 | 496 | 0.050 |
Why?
| Brain | 1 | 2013 | 2669 | 0.050 |
Why?
| Ketones | 1 | 2021 | 47 | 0.050 |
Why?
| Breath Tests | 1 | 2021 | 87 | 0.050 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 430 | 0.040 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2021 | 93 | 0.040 |
Why?
| Pregnancy Trimester, Second | 1 | 2020 | 77 | 0.040 |
Why?
| Learning | 1 | 2004 | 401 | 0.040 |
Why?
| Self Concept | 1 | 2002 | 237 | 0.040 |
Why?
| Gestational Age | 1 | 2003 | 874 | 0.040 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2020 | 39 | 0.040 |
Why?
| Birth Weight | 1 | 2003 | 505 | 0.040 |
Why?
| Skin | 1 | 2004 | 726 | 0.040 |
Why?
| Vascular Resistance | 1 | 2021 | 370 | 0.040 |
Why?
| Polyunsaturated Alkamides | 1 | 2019 | 6 | 0.040 |
Why?
| Databases, Factual | 1 | 2004 | 1266 | 0.040 |
Why?
| Capsaicin | 1 | 2019 | 25 | 0.040 |
Why?
| Arachidonic Acids | 1 | 2019 | 59 | 0.040 |
Why?
| Data Accuracy | 1 | 2019 | 57 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 332 | 0.040 |
Why?
| Immunoblotting | 1 | 2019 | 305 | 0.040 |
Why?
| Internationality | 1 | 2019 | 149 | 0.040 |
Why?
| Sleep | 2 | 2015 | 684 | 0.040 |
Why?
| Microscopy, Polarization | 1 | 2018 | 31 | 0.040 |
Why?
| Sodium | 1 | 2019 | 205 | 0.040 |
Why?
| Osmolar Concentration | 1 | 2018 | 166 | 0.040 |
Why?
| Retinol-Binding Proteins, Plasma | 1 | 2017 | 6 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 285 | 0.040 |
Why?
| Resistin | 1 | 2017 | 11 | 0.040 |
Why?
| Survival Rate | 1 | 2022 | 1869 | 0.030 |
Why?
| Lipocalin-2 | 1 | 2017 | 75 | 0.030 |
Why?
| North America | 1 | 2018 | 291 | 0.030 |
Why?
| Lost to Follow-Up | 1 | 2017 | 21 | 0.030 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2017 | 68 | 0.030 |
Why?
| Recombinant Fusion Proteins | 1 | 2020 | 648 | 0.030 |
Why?
| Seminiferous Tubules | 1 | 2016 | 12 | 0.030 |
Why?
| Semen | 1 | 2016 | 17 | 0.030 |
Why?
| Hypersensitivity, Delayed | 1 | 2016 | 28 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2018 | 541 | 0.030 |
Why?
| Drug Resistance | 1 | 2017 | 166 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2018 | 588 | 0.030 |
Why?
| Models, Economic | 1 | 2016 | 53 | 0.030 |
Why?
| Research Personnel | 1 | 2017 | 155 | 0.030 |
Why?
| Cost Savings | 1 | 2016 | 78 | 0.030 |
Why?
| Edema | 1 | 2016 | 124 | 0.030 |
Why?
| Polymorphism, Genetic | 2 | 2010 | 639 | 0.030 |
Why?
| Kidney | 1 | 2023 | 1385 | 0.030 |
Why?
| Physician-Patient Relations | 1 | 2020 | 538 | 0.030 |
Why?
| Flowers | 1 | 2016 | 61 | 0.030 |
Why?
| Antibodies, Bacterial | 1 | 2016 | 137 | 0.030 |
Why?
| Drug Monitoring | 1 | 2017 | 216 | 0.030 |
Why?
| Adiponectin | 1 | 2017 | 235 | 0.030 |
Why?
| Equipment and Supplies | 1 | 2015 | 41 | 0.030 |
Why?
| Gas Chromatography-Mass Spectrometry | 1 | 2015 | 130 | 0.030 |
Why?
| Body Burden | 1 | 2015 | 7 | 0.030 |
Why?
| C-Peptide | 1 | 2015 | 163 | 0.030 |
Why?
| Neoplasms | 1 | 2009 | 2449 | 0.030 |
Why?
| Interleukin-2 | 1 | 2016 | 437 | 0.030 |
Why?
| Salmonella typhimurium | 1 | 2016 | 174 | 0.030 |
Why?
| Communication | 1 | 2020 | 836 | 0.030 |
Why?
| Academic Medical Centers | 1 | 2017 | 474 | 0.030 |
Why?
| Genotype | 2 | 2010 | 1835 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 381 | 0.030 |
Why?
| Liver | 1 | 2022 | 1839 | 0.030 |
Why?
| Cost-Benefit Analysis | 1 | 2016 | 569 | 0.030 |
Why?
| Prenatal Diagnosis | 1 | 2015 | 190 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2020 | 892 | 0.030 |
Why?
| Health Services Accessibility | 1 | 2020 | 899 | 0.030 |
Why?
| Data Display | 1 | 2013 | 20 | 0.030 |
Why?
| Testosterone | 1 | 2016 | 372 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 833 | 0.030 |
Why?
| E-Selectin | 1 | 2013 | 54 | 0.030 |
Why?
| Electronic Health Records | 1 | 2020 | 970 | 0.030 |
Why?
| Chemokine CXCL10 | 1 | 2013 | 35 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2018 | 2117 | 0.030 |
Why?
| Risk | 1 | 2015 | 854 | 0.020 |
Why?
| Interleukin-6 | 1 | 2016 | 720 | 0.020 |
Why?
| Statistics as Topic | 1 | 2013 | 306 | 0.020 |
Why?
| Bone and Bones | 1 | 2015 | 295 | 0.020 |
Why?
| Tetraethylammonium | 1 | 2011 | 17 | 0.020 |
Why?
| beta Carotene | 1 | 2011 | 21 | 0.020 |
Why?
| Vitamin A | 1 | 2011 | 55 | 0.020 |
Why?
| Phenotype | 1 | 2019 | 3074 | 0.020 |
Why?
| Receptors, Calcitriol | 1 | 2010 | 54 | 0.020 |
Why?
| Calcium Chloride | 1 | 2010 | 12 | 0.020 |
Why?
| Expert Testimony | 1 | 2010 | 36 | 0.020 |
Why?
| Serotonin Antagonists | 1 | 2010 | 31 | 0.020 |
Why?
| Cholesterol | 1 | 2012 | 412 | 0.020 |
Why?
| Benzimidazoles | 1 | 2011 | 162 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2015 | 815 | 0.020 |
Why?
| Nitrites | 1 | 2010 | 83 | 0.020 |
Why?
| Intracellular Space | 1 | 2010 | 69 | 0.020 |
Why?
| Extracellular Space | 1 | 2010 | 120 | 0.020 |
Why?
| Potassium | 1 | 2010 | 143 | 0.020 |
Why?
| Vasoconstrictor Agents | 1 | 2010 | 127 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2010 | 237 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 947 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2017 | 2737 | 0.020 |
Why?
| Serotonin | 1 | 2010 | 318 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| Long-Term Care | 1 | 2007 | 92 | 0.020 |
Why?
| Insurance, Health, Reimbursement | 1 | 2007 | 93 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 52 | 0.020 |
Why?
| Fatty Acids | 1 | 2010 | 426 | 0.020 |
Why?
| Peptides | 1 | 2011 | 923 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1722 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1946 | 0.010 |
Why?
| Fructosamine | 1 | 2005 | 15 | 0.010 |
Why?
| Hemoglobins | 1 | 2007 | 339 | 0.010 |
Why?
| Age Distribution | 1 | 2005 | 372 | 0.010 |
Why?
| Sex Distribution | 1 | 2005 | 359 | 0.010 |
Why?
| Tomography, X-Ray Computed | 2 | 2003 | 2515 | 0.010 |
Why?
| Hemoglobinuria | 1 | 2003 | 3 | 0.010 |
Why?
| Sex Characteristics | 1 | 2003 | 736 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 1984 | 0.010 |
Why?
| Insulin Resistance | 1 | 2003 | 1165 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|